Document is current
Any future updates will be listed below
-
Authors
Miyakawa, Yoshitaka https://orcid.org/0000-0002-4429-7227
Sato, Eriko
Ogawa, Yoshiaki
Nishimura, Jun-ichi
Nishimi, Masashi
Kawaguchi, Osamu
Tahara, Sayaka
Yamaguchi, Masaki
-
Funding
Funding for this research was provided by:
Sanofi K.K.
- License Information
-
More Information
Article History
Received: 24 January 2024
Revised: 19 August 2024
Accepted: 28 August 2024
First Online: 14 October 2024
Declarations
:
: YM received research grants from Sanofi K.K., Pfizer Japan Inc., Novartis Pharma K.K., Kissei Pharmaceutical Co., Ltd., Argenx Japan K.K., Novo Nordisk Pharma Ltd., CSL Behring K.K., BioMarin Pharmaceutical Japan K.K., Chugai Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K. and received lecture fees from Sanofi K.K., Asahi Kasei Medical Co., Ltd., Takeda Pharmaceutical Co. Ltd., Alexion Pharmaceuticals, Inc., Kissei Pharmaceutical Co. Ltd., and Kyowa Kirin Co., Ltd. and participated in advisory boards held by Sanofi K.K. and Pfizer Japan Inc and was involved in consultancy for Argenx Japan K.K., Zenyaku Holdings Co., Ltd., and Kissei Pharmaceutical Co., Ltd. YO received research grants from Mochida Pharmaceutical Co., Ltd., Fortrea Japan Inc., Janssen Pharmaceutical K.K., FUJIFILM K.K., AbbVie GK., and Otsuka Pharmaceutical Co., Ltd. and received honoraria/payment from Novartis Pharma K.K, Chugai Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., and AbbVie GK. JN received honoraria or lecture fee from Swedish Orphan Biovitrum Japan K.K, Alexion Pharmaceuticals, Inc., Roche Diagnostics K.K., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., BioCryst Pharmaceuticals, Inc., and Sanofi K.K. MN and OK are employees at Sanofi K.K. and ST was employee at Sanofi K.K at the time when the Japan OLE study was conducted and the data were analyzed. ES and MY have no conflict of interest to declare.
